Other Lipid-Related Conditions
Research has shown that lower levels of cholesteryl ester transfer
protein (CETP) concentrations are associated with a decreased risk for
other cardiometabolic and neurodegenerative diseases.1,2
CETP and
Type 2 Diabetes
Pre-clinical data suggest that CETP inhibition could be a potential promising approach to improve beta cell function in type 2 diabetes by reducing free cholesterol accumulation in ß-cell islets, which may contribute to ß-cell dysfunction.3
CETP and
Alzheimer’s Disease
Preclinical and genetic studies have shown that CETP loss-of-function (LoF) genotype may be associated with reduced risk of ApoE4-associated Alzheimer’s disease.4
Our Clinical Programs
Learn more about obicetrapib, an investigational novel CETP inhibitor
1. Liu Q, Zhang J. Lipid metabolism in Alzheimer’s disease. Neuroscience Bulletin. 2014:30(2): 331-345. doi:10.1007/s12264-013-1410-3 2. Parhofer KG. Interaction between glucose and lipid metabolism: more than diabetic dyslipidemia. Diabetes and Metabolism Journal. 2015;39(5): 353-362. doi:10.4093/dmj.2015.39.5.353 3. Guo W, Gong Y, Fu Z, et al. The effect of cholesteryl ester transfer protein on pancreatic beta cell dysfunction in mice. Nutr Metab (Lond). 2016;13:21. doi:10.1186/s12986-016-0082-1 4. Tsai LH, Lindquist S, Sienski G, Narayan P et al. APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia. Science Translational Medicine. 2021;3;13(583). doi: 10.1126/scitranslmed.aaz4564.